Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.

Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”

In this video interview, Sara M. Tolaney, MD, MPH, discusses the individualized sequential therapies provided to patients based on the breast cancer subtype, genomics and other factors.

In this video interview, Sara M. Tolaney, MD, MPH, highlights the increasing incidence in breast cancer.

In this video interview, Sara M. Tolaney, MD, MPH, discusses the approvals of antibody-drug conjugates and oral targeted agents that improve outcomes among patients with breast cancer.

In this video interview, Sara M. Tolaney, MD, MPH, highlights the integration of artificial intelligence in radiologic reads to assist technicians in detecting abnormalities during breast cancer screenings.

In this video interview, Sara M. Tolaney, MD, MPH, highlights the efficacy of low-dose tamoxifen used for breast cancer prevention.

In this video interview, Sara M. Tolaney, MD, MPH, discusses the need to address disparities among patients with breast cancer.

Healio spoke with Sara M. Tolaney, MD, MPH, about unmet needs that need to be addressed in metastatic breast cancer.